Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
7.18M | 7.57M | 5.12M | 9.03M | 12.00M | 0.00 | Gross Profit |
5.15M | 5.71M | 4.38M | 8.31M | 11.53M | -229.00K | EBIT |
-55.45M | -65.92M | -65.76M | -21.30M | -30.91M | -40.18M | EBITDA |
-56.36M | -65.90M | -62.20M | -21.60M | -30.31M | -39.43M | Net Income Common Stockholders |
-65.99M | -76.58M | -67.00M | -27.68M | -38.90M | -45.50M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
59.95M | 46.33M | 69.55M | 34.27M | 70.35M | 65.47M | Total Assets |
68.64M | 54.13M | 81.60M | 44.72M | 80.13M | 74.15M | Total Debt |
1.45M | 45.94M | 45.51M | 1.53M | 43.41M | 35.31M | Net Debt |
-58.50M | -390.00K | -24.04M | -32.75M | 27.66M | 24.63M | Total Liabilities |
3.79M | 63.99M | 61.83M | 4.69M | 47.52M | 41.17M | Stockholders Equity |
64.85M | -9.86M | 19.76M | 40.03M | 32.60M | 32.99M |
Cash Flow | Free Cash Flow | ||||
-53.68M | -60.95M | -38.94M | -18.95M | -28.46M | -31.68M | Operating Cash Flow |
-53.66M | -60.93M | -38.58M | -18.65M | -27.58M | -30.21M | Investing Cash Flow |
-19.00K | -19.00K | -362.00K | 54.04M | -998.00K | -3.58M | Financing Cash Flow |
34.33M | 37.73M | 74.21M | -16.87M | 33.65M | 35.23M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
53 Neutral | $56.57M | ― | -1546.58% | ― | -19.45% | 31.22% | |
51 Neutral | $53.17M | ― | -59.49% | ― | 21.15% | 46.44% | |
50 Neutral | $77.25M | ― | -119.22% | ― | ― | 25.51% | |
46 Neutral | $57.50M | ― | -290.21% | ― | -100.00% | 44.28% | |
43 Neutral | $71.62M | ― | -679.15% | ― | -56.88% | -57.57% | |
40 Underperform | $50.39M | ― | -32.66% | ― | ― | 21.33% |
On June 5, 2025, Verrica Pharmaceuticals held its annual stockholders meeting where four proposals were considered. All three director nominees were elected, executive compensation was approved, KPMG LLP’s appointment as the accounting firm was ratified, and a potential reverse stock split was authorized, reflecting strong shareholder support for the company’s strategic decisions.
The most recent analyst rating on (VRCA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
On April 22, 2025, Verrica Pharmaceuticals announced the resignation of Christopher G. Hayes from his roles as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary, effective April 30, 2025. In connection with his resignation, the company entered into a Release Agreement with Hayes, offering him a continuation of his base salary and health coverage for up to 12 months, highlighting the company’s commitment to ensuring a smooth transition.
On March 31, 2025, Verrica Pharmaceuticals Inc. appointed Dr. Gavin Corcoran as a Class I director, with his term expiring at the 2025 annual meeting of stockholders. Dr. Corcoran, who has extensive experience in the pharmaceutical industry, will receive stock options and an annual retainer as part of his compensation, aligning with the company’s policy for non-employee directors.